Literature DB >> 19370805

Neoadjuvant chemotherapy for locally advanced squamous cancers of the head and neck: current status and future prospects.

Sreenivasa R Chandana1, Barbara A Conley.   

Abstract

PURPOSE OF REVIEW: To assess the role of neoadjuvant chemotherapy for locally advanced squamous head and neck cancer. RECENT
FINDINGS: Several phase III clinical trials in locally advanced squamous head and neck cancer show promising results for neoadjuvant platinum, taxane, and fluorouracil chemotherapy prior to definitive radiation or concurrent chemoradiation.
SUMMARY: Clinical trials comparing cisplatin and 5-fluorouracil with or without a taxane followed by radiation or concurrent chemoradiation show that the three-drug induction chemotherapy may improve survival particularly for unresectable tumors. Clinical trials comparing chemoradiation with and without induction three-drug chemotherapy are ongoing. Molecular and clinical considerations for using neoadjuvant chemotherapy in the treatment of locally advanced head and neck cancers are being explored.

Entities:  

Mesh:

Year:  2009        PMID: 19370805     DOI: 10.1097/cco.0b013e328329abe5

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  9 in total

1.  Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.

Authors:  Michael W Sim; Patrick T Grogan; Chitra Subramanian; Carol R Bradford; Thomas E Carey; M Laird Forrest; Mark E Prince; Mark S Cohen
Journal:  Laryngoscope       Date:  2015-12-21       Impact factor: 3.325

Review 2.  Emerging drugs for head and neck cancer.

Authors:  Yihui Wen; Jennifer R Grandis
Journal:  Expert Opin Emerg Drugs       Date:  2015-03-31       Impact factor: 4.191

3.  Carrier-based intralymphatic cisplatin chemotherapy for the treatment of metastatic squamous cell carcinoma of the head & neck.

Authors:  Shuang Cai; Yumei Xie; Neal M Davies; Mark S Cohen; M Laird Forrest
Journal:  Ther Deliv       Date:  2010-08

4.  Resection and reconstruction of the carotid artery for head and neck squamous cell carcinoma: a GETTEC study.

Authors:  Yonjae Kim; Pierre Philouze; Olivier Malard; Xavier Dufour; Lara Nokovitch; Philippe Céruse; Philippe Zrounba; Charles Maquet; Sophie Deneuve
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-03-31       Impact factor: 3.236

5.  Polysilsesquioxane nanoparticles for triggered release of cisplatin and effective cancer chemoradiotherapy.

Authors:  Joseph Della Rocca; Michael E Werner; Stephanie A Kramer; Rachel C Huxford-Phillips; Rohit Sukumar; Natalie D Cummings; Juan L Vivero-Escoto; Andrew Z Wang; Wenbin Lin
Journal:  Nanomedicine       Date:  2014-07-17       Impact factor: 5.307

6.  Combination of taxanes, cisplatin and fluorouracil as induction chemotherapy for locally advanced head and neck cancer: a meta-analysis.

Authors:  Hao Qin; Jie Luo; Yuan-Ping Zhu; Hai-Li Xie; Wei-Qiang Yang; Wen-Bin Lei
Journal:  PLoS One       Date:  2012-12-07       Impact factor: 3.240

Review 7.  Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma.

Authors:  Reason Wilken; Mysore S Veena; Marilene B Wang; Eri S Srivatsan
Journal:  Mol Cancer       Date:  2011-02-07       Impact factor: 27.401

8.  Clinical efficacy of neoadjuvant chemotherapy with platinum-based regimen for patients with locoregionally advanced head and neck squamous cell carcinoma: an evidence-based meta-analysis.

Authors:  Hui Chen; Liang Zhou; Dongbin Chen; Jianfeng Luo
Journal:  Ann Saudi Med       Date:  2011 Sep-Oct       Impact factor: 1.526

9.  Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck.

Authors:  Jessica Bauman; Corey Langer; Harry Quon; Kenneth Algazy; Alexander Lin; Arati Desai; Faith Mutale; Jared Weiss
Journal:  Exp Ther Med       Date:  2013-02-05       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.